Masimo Expands Its Board of Directors With Appointment of Medical Device Executive Craig Reynolds
April 04 2014 - 5:00AM
Marketwired
Masimo Expands Its Board of Directors With Appointment of Medical
Device Executive Craig Reynolds
IRVINE, CA--(Marketwired - Apr 4, 2014) - Masimo (NASDAQ: MASI),
a global innovator of noninvasive patient monitoring technologies,
today announced the appointment of seasoned medical device
executive Craig B. Reynolds to the Board of Directors of Masimo.
Reynolds also will serve as a member of the board's Audit Committee
as well as the Compensation Committee.
"Masimo has been at the forefront of medical technology
innovation, patient safety, and cost efficiencies in hospital
environments -- and has done so with ethics and integrity,"
Reynolds said. "I look forward to joining a truly impressive Board
of Directors and am confident that my medical device experience
will allow me to contribute to Masimo's continued
success."
Reynolds, 65, has served as a director of Symmetry Medical, Inc.
(NYSE: SMA) since Jan. 4, 2008, and is currently Chairman of the
Board. He is the Chief Executive Officer and a Director of Cereve,
Inc., a medical company engaged in resolving insomnia. Prior to
joining Cereve, Reynolds served as Chief Operating Officer of
Philips Respironics Home Health Solutions, a subsidiary of Philips,
from 2008 to 2010. Prior to Philips Respironics, Reynolds was the
Chief Operating Officer and a Board Member of Respironics, Inc.
(NASDAQ: RESP), a company that develops, manufactures and markets
medical devices worldwide. Reynolds also served as CEO and Director
of medical device company Healthdyne Technologies, Inc. (NASDAQ:
HDTC).
He earned his B.S. in industrial management from the Georgia
Institute of Technology and his M.B.A. from Georgia State
University.
"We are honored to have a professional of Craig's caliber on our
team," said Masimo Chairman and CEO Joe Kiani. "Craig brings a
unique combination of Executive and Board experience from the
medical technology sector as well as a long track record of doing
the right things the right way. As a result, I am confident that he
will be a valuable member of our board."
About Masimo Masimo (NASDAQ: MASI) is the global leader in
innovative noninvasive monitoring technologies that significantly
improve patient care-helping solve "unsolvable" problems. In 1995,
the company debuted Measure-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET®, which virtually eliminated false
alarms and increased pulse oximetry's ability to detect
life-threatening events. More than 100 independent and objective
studies have shown that Masimo SET® outperforms other pulse
oximetry technologies, even under the most challenging clinical
conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC�),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI®, in
addition to SpO2, pulse rate, and perfusion index (PI). Additional
information about Masimo and its products may be found at
www.masimo.com.
Masimo, SET, Signal Extraction Technology, Improving Patient
Outcome and Reducing Cost of Care... by Taking Noninvasive
Monitoring to New Sites and Applications, rainbow, SpHb, SpOC,
SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo
Corporation.
Media Contacts: Mike Drummond Masimo Corporation Phone: (949)
297-7434 Email: mdrummond@masimo.com
Respironics (NASDAQ:RESP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Respironics (NASDAQ:RESP)
Historical Stock Chart
From Apr 2023 to Apr 2024
